We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
(-16%)
Cap. Flow
-$34.7M
Cap. Flow
% of AUM
-23.28%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$2.73M |
| 2 |
Pfizer
PFE
|
+$2.42M |
| 3 |
argenx
ARGX
|
+$2.33M |
| 4 |
VYNE Therapeutics
VYNE
|
+$2.08M |
| 5 |
Invesco NASDAQ 100 ETF
QQQM
|
+$1.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$3.38M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$2.95M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$2.75M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$2.58M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.47% |
| 2 | Real Estate | 11.94% |
| 3 | Financials | 4.93% |
| 4 | Consumer Discretionary | 2.41% |
| 5 | Industrials | 2.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
| $1.68M | 1.13% |
137,000
+2,000
| +1% | +$18.2K |
|
|
MFA
27
MFA Financial
MFA
$960M
| $1.61M | 1.08% |
142,725
-60,000
| -30% | -$606K |
|
28
Immunovant
IMVT
$8.27B
| $1.6M | 1.07% |
38,000
| – | – |
|
|
29
VYNE Therapeutics
VYNE
$25.4M
| $1.56M | 1.05% |
+668,151
| New | +$2.08M |
|
30
MGIC Investment
MTG
$6.23B
| $1.53M | 1.03% |
79,379
| – | – |
|
31
Mirum Pharmaceuticals
MIRM
$7.25B
| $1.48M | 0.99% |
+50,000
| New | +$1.51M |
|
32
Equity Lifestyle Properties
ELS
$12.8B
| $1.45M | 0.98% |
20,611
| – | – |
|
|
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.43M | 0.96% |
20,000
-5,500
| -22% | -$316K |
|
|
COOP
34
DELISTED
Mr. Cooper
COOP
| $1.41M | 0.94% |
21,591
-9,699
| -31% | -$573K |
|
|
DVAX
35
DELISTED
Dynavax Technologies
DVAX
| $1.4M | 0.94% |
100,000
-10,000
| -9% | -$139K |
|
|
ONC
36
BeOne Medicines Ltd
ONC
$32.4B
| $1.35M | 0.91% |
+7,500
| New | +$1.36M |
|
37
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.35M | 0.91% |
14,000
-2,500
| -15% | -$221K |
|
|
MITT
38
TPG Mortgage Investment Trust
MITT
$243M
| $1.33M | 0.89% |
208,879
| – | – |
|
39
GSK
GSK
$104B
| $1.3M | 0.87% |
35,000
-15,000
| -30% | -$538K |
|
40
Jazz Pharmaceuticals
JAZZ
$15.5B
| $1.29M | 0.87% |
10,500
-16,000
| -60% | -$2M |
|
41
Symbotic
SYM
$5.25B
| $1.28M | 0.86% |
25,000
| – | – |
|
42
Intuitive Surgical
ISRG
$122B
| $1.27M | 0.85% |
3,750
| – | – |
|
43
Enact Holdings
ACT
$6.49B
| $1.22M | 0.82% |
42,367
| – | – |
|
44
Structure Therapeutics
GPCR
$3.45B
| $1.22M | 0.82% |
+30,000
| New | +$1.72M |
|
45
Verastem
VSTM
$530M
| $1.22M | 0.82% |
150,000
| – | – |
|
46
Royalty Pharma
RPRX
$25.8B
| $1.12M | 0.75% |
+40,000
| New | +$1.1M |
|
|
VRNA
47
DELISTED
Verona Pharma
VRNA
| $1.11M | 0.75% |
56,000
| – | – |
|
|
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $1.11M | 0.74% |
3,500
+2,750
| +367% | +$535K |
|
|
RWT
49
Redwood Trust
RWT
$641M
| $1.09M | 0.73% |
146,593
| – | – |
|
50
Synopsys
SNPS
$73.6B
| $1.08M | 0.73% |
2,100
| – | – |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.
- AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
- AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
- AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
- AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
- AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
- AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.
Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.